<DOC>
	<DOCNO>NCT02199171</DOCNO>
	<brief_summary>This phase I trial study side effect best dose heat carboplatin give abdomen time surgery treat patient stage II-IV ovarian , fallopian tube , peritoneal cancer . Drugs use chemotherapy , carboplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Heating oxaliplatin infuse directly area around tumor surgery may kill tumor cell .</brief_summary>
	<brief_title>Heated Carboplatin Treating Patients With Stage II-IV Ovarian , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>Primary Objectives : To determine maximum tolerate dose ( MTD ) carboplatin give HIPEC primary treatment woman advance ovarian , peritoneal , fallopian tube cancer . Secondary Objectives : 1 . To determine dose limit toxicity HIPEC carboplatin . 2 . To describe pharmacokinetic profile HIPEC carboplatin . 3 . To quantify change tissue temperature HIPEC compare conventional temperature measure ( esophageal bladder ) . 4 . To describe extent thermal damage DNA platinum adduct formation tissue result HIPEC carboplatin . OUTLINE : This dose escalation study . Patients receive hyperthermic carboplatin intraperitoneally 60 minute plan surgical cytoreductive procedure .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must histologically cytologically confirm , know highly suspect advanced ( International Federation Gynecology Obstetrics [ FIGO ] stage IIIV ) ovarian , primary peritoneal , fallopian tube cancer , schedule primary interval cytoreductive surgery If patient receive preoperative neoadjuvant chemotherapy , evidence response must document least one following : decline serum carcinoma antigen ( CA ) 125 level , least 30 % decrease sum long diameter target lesion radiographic imaging , resolution ascites pleural effusion ( ) Women race ethnic group eligible trial Gynecologic Oncology Group ( GOG ) performance status = &lt; 2 Leukocytes &gt; = 3,000/microliter ( mcL ) Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase ( SGOT ) ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase ( SGPT ) ) = &lt; 2.5 x institutional upper limit normal Creatinine within normal institutional limit OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Albumin &gt; = 2.5 mg/dL Patients diagnosis highgrade serous undifferentiated carcinoma ovarian , peritoneal , fallopian tubal origin confirm surgery Surgery achieve either gross residual disease optimal cytoreductive status define single lesion measure 1 cm great diameter ( protocol call intentional delay resection 3 tumor per patient HIPEC procedure complete ; surgeon identify tumor easily resectable technical safety aspect ) Patients must stable cardiopulmonary hemodynamic standpoint continue prolong surgery anesthesia Provision write informed consent Patients receive neoadjuvant chemotherapy whose disease progress follow least 3 cycle , define least one following : clinical deterioration ( new worsen exist ascites , carcinomatous ileus , malignant bowel obstruction , decline performance status ) , new lesion ( ) increase maximal diameter &gt; 20 % two large target lesion , rise CA125 ( increase least 10 % baseline value increase 3 value obtain every 21 day ) Cardiac pulmonary condition preclude aggressive cytoreductive surgery Patients find nongynecologic , uterine , breast primary surgery Patients gynecologic malignancy lowgrade serous borderline histology Patients suboptimal resection ( single tumor large 1 cm ) Patients core body temperature &gt; 37 degree Celsius ( C ) completion cytoreductive surgery prior HIPEC Patients receive investigational therapeutic agent Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>hyperthermic intraoperative intraperitoneal chemotherapy ( HIPEC ) carboplatin</keyword>
	<keyword>intraperitoneal ( IP ) chemotherapy</keyword>
	<keyword>cytoreductive surgery</keyword>
</DOC>